Skip to main content

Advertisement

SpringerLink
Log in

Prognostic value of textural features obtained from F-fluorodeoxyglucose (F-18 FDG) positron emission tomography/computed tomography (PET/CT) in patients with locally advanced cervical cancer undergoing concurrent chemoradiotherapy

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

To evaluate whether textural features obtained from F-18 FDG PET/CT offer clinical value that can predict the outcome of patients with locally advanced cervical cancer (LACC) receiving concurrent chemoradiotherapy (CCRT).

Methods

We reviewed the records of 68 patients with stage IIB–IVA LACC who underwent PET/CT before CCRT. Conventional metabolic parameters, shape indices, and textural features of the primary tumor were measured on PET/CT. A Cox regression model was used to examine the effects of variables on overall survival (OS) and progression-free survival (PFS).

Results

The patients included in this study were classified into two groups based on median value of PET/CT parameters. The high group of GLNU derived from GLRLM is only independent prognostic factor for PFS (HR 7.142; 95% CI 1.656–30.802; p = 0.008) and OS (HR 9,780; 95% CI 1.222–78.286; p = 0.031). In addition, GLNU derived from GLRLM (AUC 0.846, 95% CI 0.738–0.923) was the best predictor for recurrence among clinical prognostic factors and PET/CT parameters.

Conclusion

Our results demonstrated that high GLNU from GLRLM on pretreatment F-18 FDG PET/CT images, were significant prognostic factors for recurrence and death in patients with LACC receiving CCRT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.

    Article  CAS  Google Scholar 

  2. Lucia F, Visvikis D, Desseroit MC, Miranda O, Malhaire JP, Robin P, et al. Prediction of outcome using pretreatment (18)F-FDG PET/CT and MRI radiomics in locally advanced cervical cancer treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2018;45:768–86.

    Article  Google Scholar 

  3. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB–IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17:1339–48.

    Article  CAS  Google Scholar 

  4. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137–43.

    Article  CAS  Google Scholar 

  5. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144–53.

    Article  CAS  Google Scholar 

  6. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154–61.

    Article  CAS  Google Scholar 

  7. Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606–13.

    Article  CAS  Google Scholar 

  8. Thomas GM. Improved treatment for cervical cancer–concurrent chemotherapy and radiotherapy. N Engl J Med. 1999;340:1198–200.

    Article  CAS  Google Scholar 

  9. Kumar L, Gupta S. Integrating chemotherapy in the management of cervical cancer: a critical appraisal. Oncology. 2016;91(Suppl 1):8–17.

    Article  Google Scholar 

  10. Lucia F, Visvikis D, Vallières M, Desseroit MC, Miranda O, Robin P, et al. External validation of a combined PET and MRI radiomics model for prediction of recurrence in cervical cancer patients treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2019;46:864–77.

    Article  Google Scholar 

  11. Herrera FG, Prior JO. The role of PET/CT in cervical cancer. Front Oncol. 2013;3:34.

    Article  Google Scholar 

  12. Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200.

    Article  Google Scholar 

  13. Choi ES, Ha SG, Kim HS, Ha JH, Paeng JC, Han I. Total lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma. Eur J Nucl Med Mol Imaging. 2013;40:1836–42.

    Article  CAS  Google Scholar 

  14. Hyun SH, Ahn HK, Kim H, Ahn MJ, Park K, Ahn YC, et al. Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014;41:50–8.

    Article  CAS  Google Scholar 

  15. Klabatsa A, Chicklore S, Barrington SF, Goh V, Lang-Lazdunski L, Cook GJ. The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma. Eur J Nucl Med Mol Imaging. 2014;41:276–82.

    Article  CAS  Google Scholar 

  16. Maffione AM, Ferretti A, Grassetto G, Bellan E, Capirci C, Chondrogiannis S, et al. Fifteen different 18F-FDG PET/CT qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy. Eur J Nucl Med Mol Imaging. 2013;40:853–64.

    Article  CAS  Google Scholar 

  17. Ryu IS, Kim JS, Roh JL, Cho KJ, Choi SH, Nam SY, et al. Prognostic significance of preoperative metabolic tumour volume and total lesion glycolysis measured by (18)F-FDG PET/CT in squamous cell carcinoma of the oral cavity. Eur J Nucl Med Mol Imaging. 2014;41:452–61.

    Article  CAS  Google Scholar 

  18. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S-S150.

    Article  CAS  Google Scholar 

  19. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group, Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer. 1999;35:1773–82.

    Article  Google Scholar 

  20. Han S, Kim H, Kim YJ, Suh CH, Woo S. Prognostic value of volume-based metabolic parameters of (18)F-FDG PET/CT in uterine cervical cancer: a systematic review and meta-analysis. AJR Am J Roentgenol. 2018;211:1112–21.

    Article  Google Scholar 

  21. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92.

    Article  CAS  Google Scholar 

  22. Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer. 2010;103:1139–43.

    Article  CAS  Google Scholar 

  23. Ha S, Choi H, Paeng JC, Cheon GJ. Radiomics in oncological PET/CT: a methodological overview. Nucl Med Mol Imaging. 2019;53:14–29.

    Article  Google Scholar 

  24. Chung HH, Kang SY, Ha S, Kim JW, Park NH, Song YS, et al. Prognostic value of preoperative intratumoral FDG uptake heterogeneity in early stage uterine cervical cancer. J Gynecol Oncol. 2016;27: e15.

    Article  Google Scholar 

  25. Guan Y, Li W, Jiang Z, Chen Y, Liu S, He J, et al. Whole-lesion apparent diffusion coefficient-based entropy-related parameters for characterizing cervical cancers: initial findings. Acad Radiol. 2016;23:1559–67.

    Article  Google Scholar 

  26. Ho KC, Fang YH, Chung HW, Yen TC, Ho TY, Chou HH, et al. A preliminary investigation into textural features of intratumoral metabolic heterogeneity in (18)F-FDG PET for overall survival prognosis in patients with bulky cervical cancer treated with definitive concurrent chemoradiotherapy. Am J Nucl Med Mol Imaging. 2016;6:166–75.

    CAS  Google Scholar 

  27. Reuze S, Orlhac F, Chargari C, Nioche C, Limkin E, Riet F, et al. Prediction of cervical cancer recurrence using textural features extracted from 18F-FDG PET images acquired with different scanners. Oncotarget. 2017;8:43169–79.

    Article  Google Scholar 

  28. Torheim T, Groendahl AR, Andersen EK, Lyng H, Malinen E, Kvaal K, et al. Cluster analysis of dynamic contrast enhanced MRI reveals tumor subregions related to locoregional relapse for cervical cancer patients. Acta Oncol. 2016;55:1294–8.

    Article  Google Scholar 

  29. Yip SS, Aerts HJ. Applications and limitations of radiomics. Phys Med Biol. 2016;61:R150–66.

    Article  CAS  Google Scholar 

  30. Chong GO, Lee WK, Jeong SY, Park SH, Lee YH, Lee SW, et al. Prognostic value of intratumoral metabolic heterogeneity on F-18 fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced cervical cancer patients treated with concurrent chemoradiotherapy. Oncotarget. 2017;8:90402–12.

    Article  Google Scholar 

  31. Chen SW, Shen WC, Hsieh TC, Liang JA, Hung YC, Yeh LS, et al. Textural features of cervical cancers on FDG-PET/CT associate with survival and local relapse in patients treated with definitive chemoradiotherapy. Sci Rep. 2018;8:11859.

    Article  Google Scholar 

  32. Nioche C, Orlhac F, Boughdad S, Reuze S, Goya-Outi J, Robert C, et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. 2018;78:4786–9.

    Article  CAS  Google Scholar 

  33. Herrera FG, Breuneval T, Prior JO, Bourhis J, Ozsahin M. [(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy. Radiat Oncol. 2016;11:43.

    Article  Google Scholar 

  34. McDonald JE, Kessler MM, Gardner MW, Buros AF, Ntambi JA, Waheed S, et al. Assessment of total lesion glycolysis by (18)F FDG PET/CT significantly improves prognostic value of GEP and ISS in Myeloma. Clin Cancer Res. 2017;23:1981–7.

    Article  CAS  Google Scholar 

  35. Yoon H, Ha S, Kwon SJ, Park SY, Kim J, et al. Prognostic value of tumor metabolic imaging phenotype by FDG PET radiomics in HNSCC. Ann Nucl Med. 2021;35:370–7.

    Article  CAS  Google Scholar 

  36. Shiri I, Sorouri M, Geramifar P, Nazari M, Abdollahi M, Salimi Y, et al. Machine learning-based prognostic modeling using clinical data and quantitative radiomic features from chest CT images in COVID-19 patients. Comput Biol Med. 2021;132: 104304.

    Article  CAS  Google Scholar 

  37. Mu W, Liang Y, Hall LO, Tan Y, Balagurunathan Y, Wenham R, et al. (18)F-FDG PET/CT habitat radiomics predicts outcome of patients with cervical cancer treated with chemoradiotherapy. Radiol Artif Intell. 2020;2: e190218.

    Article  Google Scholar 

  38. Esfahani SA, Torrado-Carvajal A, Amorim BJ, Groshar D, Domachevsky L, Bernstine H, et al. PET/MRI and PET/CT radiomics in primary cervical cancer: a pilot study on the correlation of pelvic PET, MRI, and CT derived image features. Mol Imaging Biol. 2022;24:60–9.

    Article  CAS  Google Scholar 

  39. Hatt M, Tixier F, Pierce L, Kinahan PE, Le Rest CC, Visvikis D. Characterization of PET/CT images using texture analysis: the past, the present any future? Eur J Nucl Med Mol Imaging. 2017;44:151–65.

    Article  Google Scholar 

Download references

Acknowledgements

We are thankful to the data providers for sharing their precious resources.

Funding

No funding.

Author information

Author notes

  1. Hyun-Woong Cho and Eun Seong Lee contributed equally to this work.

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Korea University Guro Hospital, Korea University College of Medicine, 148, Gurodong-Ro, Guro-Gu, Seoul, 08308, Republic of Korea

    Hyun-Woong Cho, Jae Kwan Lee & Jin Hwa Hong

  2. Department of Nuclear Medicine, Korea University Guro Hospital, Korea University College of Medicine, 148, Gurodong-Ro, Guro-Gu, Seoul, 08308, Republic of Korea

    Eun Seong Lee & Jae Seon Eo

  3. Department of Nuclear Medicine, Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea

    Sungeun Kim

Authors
  1. Hyun-Woong Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eun Seong Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jae Kwan Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jae Seon Eo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sungeun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jin Hwa Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Protocol/project development: CHW, LES, EJS, HJH. Data collection or management: CHW, LES, EJS, HJH, KS. Data analysis: CHW, LES. Manuscript writing/editing: CHW, LES, EJS, HJH, KS.

Corresponding authors

Correspondence to Jae Seon Eo or Jin Hwa Hong.

Ethics declarations

Conflict of interest

No potential conflicts of interest were disclosed.

Ethical approval

This study was approved by the Medical Research Review Committee of Korea University Guro Hospital (IRB approval number: 2019GR0318).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cho, HW., Lee, E.S., Lee, J.K. et al. Prognostic value of textural features obtained from F-fluorodeoxyglucose (F-18 FDG) positron emission tomography/computed tomography (PET/CT) in patients with locally advanced cervical cancer undergoing concurrent chemoradiotherapy. Ann Nucl Med 37, 44–51 (2023). https://doi.org/10.1007/s12149-022-01802-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-022-01802-z

Keywords

Search

Navigation